Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02541604 · OUTCOME

Atezolizumab Serum Concentration at Washout

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors · Source last updated 2020-02-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
ug/mL
Interval / dispersion
Geometric Coefficient of Variation
Time frame
At least 90 days (maximum 150 days) after last dose of study drug (up to approximately 42 months)

Analysis population: Included PK population, defined as patients who had received any amount of study drug and had at least one serum concentration result available at clinical data cutoff.

Groups in this outcome

Atezolizumab

Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams \[mg\]) on Day 1 of each 21-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab17

Reported measurements

Source class 1
Values in ug/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Atezolizumab1.912815.1Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        2815.1
        value
        1.91
denoms
  1. counts
    1. group Id
      OG000
      value
      17
    units
    Participants
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams \[mg\]) on Day 1 of each 21-day cycle.
    id
    OG000
    title
    Atezolizumab
param Type
GEOMETRIC_MEAN
population Description
Included PK population, defined as patients who had received any amount of study drug and had at least one serum concentration result available at clinical data cutoff.
reporting Status
POSTED
time Frame
At least 90 days (maximum 150 days) after last dose of study drug (up to approximately 42 months)
title
Atezolizumab Serum Concentration at Washout
type
PRIMARY
unit Of Measure
ug/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice